Europe's Alzheimer's research needs generational renewal, warns neurology expert
In an interview with Euractiv during the 'Mind the Future' summit in Milan, Tibor Kovács, Full Professor and Deputy Director at the Department of Neurology at Semmelweis University in Budapest, welcomed the growing momentum behind international cooperation on dementia. But he also issued a warning: cooperation is not the problem - implementation is.
'There is extensive collaboration through various European and international grants,' Kovács said, welcoming the increasing involvement of less-resourced partners in cutting-edge research through inclusive application systems. 'The trend is clearly moving in a positive direction, which is promising for the future.'
However, turning research into patient care remains a much tougher task. 'When it comes to translating that research into clinical practice, things become much more dependent on national contexts,' he explained. In other words, supranational efforts may push the frontier of discovery, but clinical neuroscience still lives - and often stalls - within domestic borders.
Keep it local
Any common European regulation, he added, would still need to be adapted to local realities: 'Applied and clinical research must be grounded in specific national circumstances.' Despite these challenges, Kovács remains cautiously hopeful: more funding, he said, could help smaller institutions take part in research at the highest level.
And in Hungary, that kind of shift is sorely needed. While the country has long had a strong tradition in neuroscience, Kovács pointed out that this strength lies mainly in basic science, not in clinical applications. 'We still face a lot of handicaps,' he said, particularly when it comes to the use of new biomarkers for early diagnosis of degenerative dementias.
A few centres in Hungary are conducting high-level clinical research on dementias and movement disorders, but staffing shortages and limited resources continue to slow progress. For Kovács, the solution must begin with generational renewal: 'We need to attract young researchers into the field, starting from university years.'
The challenge isn't a lack of talent - quite the opposite. Many Hungarian researchers, he said, are working on neurodegenerative diseases abroad. 'The idea,' he added, 'is to bring those brains back and improve the local research environment.'
Until then, the gap between what is discovered and what is delivered will remain. And for countries like Hungary, bridging that gap is now the real frontier.
Alessia Peretti, Cesare Ceccato
[Edited By Brian Maguire | Euractiv's Advocacy Lab ]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euractiv
3 hours ago
- Euractiv
Final journey: The divide within Europe over euthanasia and assisted dying
Every year, dozens of terminally ill patients from across Europe travel to Belgium and Switzerland, not in search of hope, but of a dignified death. With euthanasia and assisted dying still illegal in most EU countries, many have no choice but to cross borders to end their suffering. Such a discrepancy in how the issue is handled across Europe makes it difficult for those experiencing chronic illness to plan a dignified end to the lives close to home. In 2024, 120 patients travelled to Belgium for euthanasia, of which 102 were French nationals. Belgium remains the only EU country where euthanasia is legal for foreigners. The practice – defined as a doctor directly administering a lethal substance – is strictly regulated, yet accessible across borders. These cases have often cynically been described as 'death tourism'. But as Anne Raynaud, head of youth at the French Association for the Right to Die with Dignity (ADMD), points out: "For most end-of-life patients, requesting euthanasia is far from 'tourism'." The reason so many French patients cross the border is simple, she adds: 'Those who want to choose the terms of their end of life currently have no option in France.' A survey of European policies The French are not alone in their frustration. When it comes to terminally ill patients, only a few countries offer legal options for ending life. Belgium, Luxembourg, the Netherlands, Portugal, and Spain have legalised euthanasia, but access is generally limited to their own citizens or residents. Assisted dying – where patients administer life-ending medication themselves – is legal in Austria and Germany, following court rulings in 2019 and 2022. Switzerland is the only European country that allows foreigners to access assisted dying, although it does not keep official statistics on this. Dignitas, the country's best-known provider, reported 280 assisted deaths last year – its highest on record. Most were foreign nationals, 57 from France, 37 from the UK, and 22 from Italy. The UK has recently taken the first steps toward an assisted dying bill. Tuscany, a region of Italy, has also passed a law allowing assisted dying and carried out its first assisted death in June, a possible blueprint for other regions. Meanwhile, France's National Assembly voted in May to permit assisted dying, but the bill must still pass the more conservative Senate in autumn, though there is no clear division along party lines. Even a strictly Catholic country as Malta, where abortion is forbidden, is debating the topic now as the government has launched a public consultation to ask its citizens for their views on assisted voluntary euthanasia. Also, in countries that have previously refused to legalise assisted dying or euthanasia, the topic continues to reappear on the agenda. For example, in Czechia, it is a key issue ahead of the upcoming parliamentary elections in October. But not all national debates are moving forward. In Slovenia, a top state body vetoed a new assisted dying bill, warning that it raised unresolved ethical, legal and philosophical questions. Nevertheless, according to ADMD's Anne Raynaud, many patients understand that even if laws are eventually passed, their implementation "will likely take many months". "Sadly, many of them do not have that kind of time and are forced to go abroad to end their suffering," she said. An EU blind spot Despite clear demand, the European Commission has explicitly said it won't act. In response to MEP queries, the Commission said that "responsibility for healthcare, including care for terminally ill patients, as well as ethical questions, rests with the Member States." The lack of legal options within the EU is particularly affecting Switzerland, where Dignitas would at least like to see international guidelines. "An international approach is necessary because the hopes, wishes, and needs of people are quite similar in most places around the world," the organisation argues, but one that also respects "cultural and social context." The Swiss association EXIT, which supports only Swiss nationals and residents with assisted dying, takes a more pragmatic stance: "A pan-European regulation is neither necessary nor realistic," the association said in response to a request from Euractiv . In EXIT's view, it would be sufficient if every European country legalised euthanasia. Germany's experience shows how national laws can make a difference. After the country legalised assisted dying, the number of German nationals travelling to Switzerland dropped sharply – from 85 a year to just five in 2023. Raynaud of ADMD warns that assisted dying isn't an option for everyone. "Patients who are physically unable to self-administer the lethal substance cannot benefit from it." There is also a stark economic divide. In Switzerland, assisted dying can cost over €10,000. In Belgium, the process is about one-tenth of that. And for many, it's not just about cost, but the emotional burden. Whether in Belgium or Switzerland, as Raynaud noted, most people would still prefer to die at home or close to loved ones. (bms, aw, cs)
Euractiv
12 hours ago
- Euractiv
Danish quantum investment will boost EU biotech and medical research
The investment in a new, powerful quantum computing hub in Denmark aims to provide a significant boost to biotech and medical research in the Nordics, according to the CEO of the Novo Nordisk Foundation. The Export and Investment Fund of Denmark (EIFO) and the Novo Nordisk Foundation have announced plans to invest €80 million in a Level 2 quantum computer. Named after the Norse god Magni, the computer is expected to be operational by 2026–2027. Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation, told Euractiv that the investment aims to provide a significant boost to biotech and medical research in Denmark, Sweden, Finland, Norway and Iceland. Computer power It is also a necessary step in generating an even more powerful computer: a level 3 quantum computer, which is expected to be ready for use by 2030 and will be a thousand times more powerful than a level 2 computer. 'Being squeezed from both the West and the East, from both the US and China, Europe is in a vulnerable position and falling behind, as the Draghi report shows. Therefore, we in Denmark would like to do our utmost to restore and strengthen our position in the Nordics.' Also, Morten Bødskov, Danish Minister of Industry, Business and Financial Affairs, stated that, 'With the investment in the world's strongest quantum computer, we are making a solid shift in the global quantum race." He added, "This will benefit all of Europe. We need to harness the untapped possibilities of quantum technology for Danish and European businesses, society, and security. Denmark and the EU must lead the race in developing new technologies.' EU-US collaboration Although primarily European, the Magne project will involve two American companies. The California-based Atom Computing will build and deliver quantum hardware for Magne, while Microsoft will integrate its Azure cloud platform software, tailored to Atom Computing's neutral atom technology . TheNovo Nordisk Foundation CEO said that all data input, such as individual health journals, will be stored in Denmark and shall not migrate outside its borders. 'No data is ever leaving Denmark,' he stated. At the same time, the next generation, the level 3 quantum computer, is planned to be fully based on European technology. Keeping research in Europe The investors are setting up a company called QuNorth to house the Magne computer in Copenhagen. Magne will be used alongside AI and hybrid computing; the latter could, for example, integrate public and private clouds or systems, or digital and analogue components of different sorts. The quantum computing hub in the Danish capital will, according to Thomsen, invite both public and private researchers to conduct advanced calculations to solve complex problems, such as those at the subatomic or molecular level, and study protein mechanisms in medical research. 'We would especially like to stimulate private and public partnerships and to keep innovation in Europe.' At the same time, 'unethical research' would probably not be allowed, but such a definition is not yet set. Empowering the Nordics Marie Arsenian-Henriksson, Vice President for Research at the renowned Swedish medical university Karolinska Institutet (KI), told Euractiv that the new initiative creates 'very favourable conditions for researchers and industrial partners in the Nordics within health and life science,' adding that: 'The QuNorth initiative consolidates and further develops the Nordic region's position as a global leader in Quantum Life Science and helps us to translate advanced quantum technology into concrete societal benefits in the field of health." This is also the view of Juleen R. Zierath, an American professor at the Department of Molecular Medicine and Surgery at KI, and affiliated with a research centre at the University of Copenhagen, financed by the Novo Nordisk Foundation. She is not directly involved in the Magne project. Usually, she explained, it is very difficult for researchers to access such modern and powerful tools. 'The new quantum computing resources will be very important and open up opportunities to find new medical advances for Nordic researchers in the future. It will be a lift for the whole ecosystem of life science –natural science, tech science and medical science – in the Nordics,' she said. Not without caveats Even so, Juleen R. Zierath also pointed to the risk of trusting AI and quantum computing too much, as answers and solutions depend on what data a researcher puts into these systems. 'Researchers and students need to have a basic understanding of how to conduct science, and that one needs to put in the highest and most accurate level of information to get the best possible outputs.' Magne will be 100% Danish-owned, with EIFO and the Novo Nordisk Foundation each investing approximately €40 million in the establishment of QuNorth. QuNorth plans to build a small organisation of around 10 employees, whose primary task will be to ensure optimal utilisation of Magne across commercial and academic users in the Nordic region. The search for a CEO for the new company is set to start soon. [Edited by Vasiliki Angouridi, Brian Maguire]
Euractiv
2 days ago
- Euractiv
EU Commission to propose partial suspension of Israel research cooperation
In a closed-door meeting on Monday, EU commissioners agreed to propose a partial suspension of the Horizon Europe research program with Israel – worth hundreds of millions – citing the ongoing humanitarian crisis in Gaza. In a quietly added, unpublicised Brussels meeting added late on Monday, top EU officials met to agree to propose a partial suspension of the research agreement – though the final decision now lies with member states. Horizon Europe is the EU's flagship research and innovation programme, which funds scientific research, tech development, and cross-border collaboration. Non-EU countries, including Israel, can take part through special association agreements –and Israel has been involved since 2021. Suspending Israel was one of the options amongst the possible measures against the country, drafted by the bloc's diplomatic service earlier this month. The move – if approved by member states – would be the first concrete sanctions imposed by Europe on Israel amid its war against Hamas in Gaza. According to an EU official, the proposal was made because the bloc sees no tangible improvement of the humanitarian situation on the ground, despite the signing of an agreement with Israel to ramp up the amount of food aid going into Gaza this month. European commissioners also discussed the tentative political deal that Commission President Ursula von der Leyen struck with the US. Israel's Academy of Sciences said in May that being expelled from the Horizon programme would be a "death sentence" for Israeli scientists. (aw)
